Durdans Hospital and Credence Genomics in partnership
21 Apr 2015 - {{hitsCtrl.values.hits}}
Durdans Hospital, a premier tertiary healthcare service provider in Sri Lanka established since 1945, has partnered with Credence Genomics (Pvt.) Ltd, Sri Lanka’s pioneering commercial next generation sequencing facility, to provide preventive and diagnostic testing based on the Credence Next Generation Sequencing (NGS) platform.
The platform allows with 99.7 percent accuracy to predict and diagnose their patients in multiple specialties not limited to but including oncology, cardiology, immunology, paediatrics and infectious disease.
Durdans Laboratory services has an islandwide network of collection centres, which can collect samples at any location in Sri Lanka and are centrally processed at its centre in Colombo.
Credence Genomics is the only company in Sri Lanka to provide genomic diagnostics to their clients, while Durdans Hospital provides excellent healthcare services. With its experience in molecular diagnostics and existing DNA-based test menu, the synergy between Credence and Durdans was a natural evolution bringing two pioneers in the industry together.
Credence Genomics’ innovative test menu allows individuals to predict, diagnose and treat cancer or inherited diseases based on gene expressions. The test allows premier healthcare providers like Durdans to monitor their patients closely, providing a better quality of life along with careful screening and treatment if applicable.
Credence’s tests also play an active role in infectious patients – Bactfast and Fungifast, which identify all known bacteria and fungus known to man in one test with the fastest turn arounds.
The collaboration between Durdans and Credence allows Durdans to provide the latest technology and advances in NGS to all their patients using their existing services.
